Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when other analgesics are insufficient. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts within the central nervous system to alleviate pain associated with several conditions. - Chronic musculoskeletal pain: Provides long‑lasting relief for persistent back or joint pain. - Neuropathic pain associated with diabetic peripheral neuropathy: Helps reduce pain intensity in affected nerves. - Cancer‑related pain: Contributes to the control of moderate‑to‑severe pain in oncology patients.

Tapentadol Hydrochloride may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach sensation. - Constipation: reduced bowel movements. - Dizziness: feeling light‑headed or unsteady. - Somnolence: increased sleepiness. - Headache: mild throbbing pain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Seizures: convulsive episodes, particularly at high doses. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of misuse with prolonged use. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Tapetone​d Hydrochloride, clinicians should consider several safety aspects. - Assess patient history: review           ...  ...  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... … … … … … … … ... ... ... ... … ... Assess  … ... "); -  ");  "  " \